Accessibility Menu
Aldeyra Therapeutics logo

Aldeyra Therapeutics(NASDAQ) ALDX

Current Price$1.71
Market Cap$102.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2014)-76%
5 Year-81%
1 Year-68%
1 Month-17%
Aldeyra Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.702026-07-22
Aldeyra Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.46%USD 1.922026-07-15
1 month-17.07%USD 2.052026-06-22
3 month+6.25%USD 1.602026-04-23
Year to date-67.18%USD 5.182025-12-31
1 year-68.28%USD 5.362025-07-22
3 year-78.72%USD 7.992023-07-21
5 year-81.26%USD 9.072021-07-23
Since inception-76.39%USD 7.202014-05-02

Aldeyra Therapeutics Financials at a Glance

Market Cap

$102.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$27.37M

EPS (TTM)

-$0.46

P/E Ratio

-3.73

Dividend

$0.00

Beta (Volatility)

1.82 (High)

Price

$1.71

Volume

63,690.914

Open

$1.70

Previous Close

$1.70

Daily Range

$1.69 - $1.71

52-Week Range

$1.07 - $6.18

Estimated Earnings Date

Aug 6, 2026

ALDX News

Red line falling $100 bill

Why Aldeyra Therapeutics Stock Is Sinking Today

Keith SpeightsApr 28, 2021
Eye drops - woman

Why Aldeyra Therapeutics Stock Is Soaring Today

Keith SpeightsApr 27, 2021
Dry eyes written on chalkboard

Why Aldeyra Therapeutics Stock Is Jumping Today

Keith SpeightsJan 14, 2021
Businessman with thumb up

Why Aldeyra Therapeutics Stock Soared Today

Keith SpeightsOct 16, 2020
raining cash getty

Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today

Maxx ChatskoMar 26, 2019

ALDX: Motley Fool Moneyball Superscore

47

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aldeyra Therapeutics

Aldeyra Therapeutics develops medicines for eye and systemic diseases. Its products target conditions like dry eye and asthma. The company aims to improve patient quality of life.

Products and Services

Reproxalap: Treats dry eye disease and allergic conjunctivitis.

ADX-629: Oral treatment for psoriasis, asthma, and COVID-19.

ADX-2191: Prevents proliferative vitreoretinopathy and treats retinitis pigmentosa.

RASP Modulator Platform: Targets multiple proteins for broad therapeutic use.

Growth and Expansion

Entered exclusive option agreement with AbbVie for reproxalap, potential $100 million upfront.

License agreement with Madrigal Pharmaceuticals for ADX-1612 development.

Focus on late-stage trials for key products to drive future growth.

Unique Features of Aldeyra

Aldeyra's approach targets multiple protein systems, optimizing pathways and minimizing toxicity. Its RASP modulator platform offers broad therapeutic potential.

Key Financial Insights

No product sales revenue; relies on future approvals.

Research expenses rose to $48.2 million in 2024.

Clinical trials involve over 2,500 patients for reproxalap.

Strategic partnerships aim to secure funding and market entry.

Operational challenges include regulatory delays and capital needs.

Bottom Line

Aldeyra focuses on innovative treatments for complex diseases. Its strategic partnerships and unique approach position it for future growth.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Todd C. Brady, MD, PhD

Website

www.aldeyra.com

Headquarters

Lexington, MA 02421, US

ALDX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-57.34%

Return on Capital

-58.99%

Return on Assets

-41.17%

Earnings Yield

-26.81%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$102.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

60.32M

Volume

63.69K

Avg. Volume

1.38M

Financials (TTM)

Gross Profit

-$66.60K

Operating Income

-$28.38M

EBITDA

-$25.22M

Operating Cash Flow

-$25.99M

Capital Expenditure

-$4.00

Free Cash Flow

-$25.99M

Cash & ST Invst.

$65.00M

Total Debt

$15.51M

Aldeyra Therapeutics Performance Analysis

Aldeyra Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Aldeyra Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Aldeyra Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.06-0.7%
20232023-12-31USD -0.64-40.0%
20242024-12-31USD -0.9447.4%
20252025-12-31USD -0.56-40.0%
Aldeyra Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-305.9%
Q32025-09-3018.8%
Q42025-12-3115.4%
Q12026-03-3148.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$66.60K

N/A

Gross Margin

0.00%

N/A

Market Cap

$102.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.82M

N/A

Employees

8

N/A

Net Income

-$3.45M

+65.2%

EBITDA

-$2.92M

+68.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$65.00M

-27.8%

Total Debt

$15.51M

-0.3%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$15.51M

+5975.3%

Return on Assets

-41.17%

N/A

Return on Invested Capital

-67.33%

N/A

Free Cash Flow

-$5.11M

+59.0%

Operating Cash Flow

-$5.11M

+59.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNLXGenelux Corporation
$2.98+0.68%
MREOMereo BioPharma Group plc
$0.30+0.40%
ACIUAC Immune S.A.
$2.24-1.32%
CLLSCellectis S.A.
$2.81+0.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$34.29-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About ALDX

What is the current price of Aldeyra Therapeutics?

Aldeyra Therapeutics is trading at $1.70 per share.

What is the 52-week range for Aldeyra Therapeutics?

Over the past 52 weeks, Aldeyra Therapeutics has traded between $1.07 and $6.18.

How much debt does Aldeyra Therapeutics have?

As of the most recent reporting period, Aldeyra Therapeutics reported total debt of $15.51M.

How much cash does Aldeyra Therapeutics have on hand?

Aldeyra Therapeutics reported $65.00M in cash and cash equivalents in its most recent financial results.

What is Aldeyra Therapeutics’s dividend yield?

Aldeyra Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services